title: Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas.
abstract: The aim of the present study was to compare the expression levels of secretogranin II (SgII), prohormone convertases (PC)1 and PC2, and the proteolytic processing of SgII in benign versus malignant pheochromocytomas. Quantitative (Q)-PCR experiments indicated that SgII, PC1, and PC2 mRNAs were overexpressed in pheochromocytoma compared to non-tumoral chromaffin cells (P<0.001) and in benign compared to malignant tumors (P<0.01). Western blot analysis using a human SgII antiserum revealed the occurrence of a 97-kDa band corresponding to the expected size of SgII, with significantly higher quantities in benign than in malignant tumors (P<0.05). Using antisera directed against sequential regions of SgII (N-terminal, secretoneurin [SN], EM66, internal, and C-terminal sequences), we observed distinct processing profiles between benign and malignant pheochromocytomas. In contrast, using PC1 and PC2 antisera no differences between the two types of tumors were found. RIA measurement showed that EM66 median values between benign and malignant chromaffin cell tumors were significantly different (128.5 vs. 6.3 ng/mg protein, respectively; P<0.001). Taken together, these results indicate that, in pheochromocytoma, malignancy is associated with reduced PC1, PC2, and SgII mRNA expression and decreased levels of processing products of SgII, in line with the low concentrations of EM66 that occur in malignant tumors. These data support the notion that SgII-processing products, such as EM66, could represent prognostic markers of pheochromocytomas.
authors.affiliation: INSERM U413, Laboratory of Cellular and Molecular Neuroendocrinology, European Institute for Peptide Research (IFRMP23), University of Rouen, 76821 Mont-Saint-Aignan, and Department of Endocrinology, Hôpital de Brabois, Nancy, France.
authors.forename: Johann
authors.initials: J
authors.lastname: Guillemot
authors.forename: Laure
authors.initials: L
authors.lastname: Barbier
authors.forename: Erwan
authors.initials: E
authors.lastname: Thouennon
authors.forename: Virginie
authors.initials: V
authors.lastname: Vallet-Erdtmann
authors.forename: Maite
authors.initials: M
authors.lastname: Montero-Hadjadje
authors.forename: Herve
authors.initials: H
authors.lastname: Lefebvre
authors.forename: Marc
authors.initials: M
authors.lastname: Klein
authors.forename: Mihaela
authors.initials: M
authors.lastname: Muresan
authors.forename: Pierre-François
authors.initials: PF
authors.lastname: Plouin
authors.forename: Nabil
authors.initials: N
authors.lastname: Seidah
authors.forename: Hubert
authors.initials: H
authors.lastname: Vaudry
authors.forename: Youssef
authors.initials: Y
authors.lastname: Anouar
authors.forename: Laurent
authors.initials: L
authors.lastname: Yon
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000473:pathology; D020869:Gene Expression Profiling; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000473:pathology; D011379:Prognosis; D011863:Radioimmunoassay